Airxpanders 10-Q 9 Nov 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 31, 2017
Document Information [Line Items]
Entity Registrant Name	AIRXPANDERS INC
Entity Central Index Key	1,387,156
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		95,943,408
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
ASSETS
Cash and cash equivalents	$ 9,875	$ 11,477
Short-term investments	20,946
Accounts receivable	751	118
Inventory	6,429	1,413
Prepaid expenses and other current assets	1,530	558
Total current assets	39,531	13,566
Property and equipment, net	4,419	1,879
Other assets	118	84
Total assets	44,068	15,529
LIABILITIES AND STOCKHOLDERS' EQUITY
Current portion of long-term debt, net of discount		1,195
Accounts payable	3,185	1,249
Accrued expenses	2,051	916
Total current liabilities	5,236	3,360
Long-term debt, less current portion, net of discount	14,520
Total liabilities	19,756	3,360
Commitments and Contingencies (Note 8)
Stockholders' equity
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued and outstanding at September 30, 2017 and December 31, 2016	0	0
Additional paid-in capital	111,863	78,418
Accumulated deficit	(87,647)	(66,328)
Total stockholders' equity	24,312	12,169
Total liabilities and stockholders' equity	44,068	15,529
Common Class A [Member]
Stockholders' equity
Common stock	96	79
Common Class B [Member]
Stockholders' equity
Common stock	$ 0	$ 0

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001
Common stock, shares authorized (in shares)	300,000,000
Common Class A [Member]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	95,906,958	79,241,708
Common stock, shares outstanding (in shares)	95,906,958	79,241,708
Common Class B [Member]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	0	0
Common stock, shares outstanding (in shares)	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Net revenue	$ 1,159	$ 159	$ 2,116	$ 375
Cost of goods sold	1,638	1,280	6,363	3,189
Gross loss	(479)	(1,121)	(4,247)	(2,814)
Operating expenses:
Research and development	1,952	1,811	6,329	5,129
Selling, general and administrative	3,371	2,266	10,586	5,976
Total operating expenses	5,323	4,077	16,915	11,105
Operating loss	(5,802)	(5,198)	(21,162)	(13,919)
Other expense (income):
Interest expense	242	50	328	170
Other expense (income), net	(44)	(19)	(172)	(19)
Total other expense (income), net	198	31	156	151
Operating loss before income tax provision	(6,000)	(5,229)	(21,318)	(14,070)
Provision for income taxes	(1)		1
Net loss	$ (5,999)	$ (5,229)	$ (21,319)	$ (14,070)
Net loss per common share: basic and diluted (in dollars per share)	$ (0.06)	$ (0.07)	$ (0.23)	$ (0.19)
Weighted-average number of common shares used in computing net loss per common share: basic and diluted (in shares)	95,901	79,201	93,104	73,898
Comprehensive Loss:
Net loss	$ (5,999)	$ (5,229)	$ (21,319)	$ (14,070)
Unrealized gain on investments	14
Total comprehensive loss	$ (5,985)	$ (5,229)	$ (21,319)	$ (14,070)

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - 9 months ended Sep. 30, 2017 - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2016	79,241,708
Balance at Dec. 31, 2016	$ 79	$ 78,418	$ (66,328)	$ 12,169
Issuance of Class A Common Stock for cash (net of issuance costs of $1,462) (in shares)	16,304,348
Issuance of Class A Common Stock for cash (net of issuance costs of $1,462)	$ 16	32,633		$ 32,649
Exercise of stock options and warrants, 388,673 shares net of 27,771 shares traded for exercise price (in shares)	360,902			27,771
Exercise of stock options and warrants, 388,673 shares net of 27,771 shares traded for exercise price	$ 1	52		$ 53
Issuance of warrants to purchase Class A Common Stock in connection with issuance of debt		227		227
Stock-based compensation		533		533
Net loss			(21,319)	(21,319)
Balance (in shares) at Sep. 30, 2017	95,906,958
Balance at Sep. 30, 2017	$ 96	$ 111,863	$ (87,647)	$ 24,312

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals)	9 Months Ended
	Sep. 30, 2017USD ($)shares
Additional Paid-in Capital [Member]
Issuance of common stock for cash, issuance costs | $	$ 1,462,000
Common Stock [Member]
Exercise of stock options and warrants, shares, exercised (in shares)	388,673
Exercise of stock options and warrants, shares traded for exercise price (in shares)	27,771

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities
Net loss	$ (21,319)	$ (14,070)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	343	226
Amortization of debt discount and deferred issuance cost	107	30
Inventory write-down and reserves	3,143	578
Stock-based compensation	533	316
Changes in operating assets and liabilities:
Accounts receivable	(633)	(134)
Inventory	(7,934)	(725)
Prepaid expenses and other assets	(991)	(654)
Accounts payable	1,032	492
Accrued expenses	909	99
Net cash used in operating activities	(24,810)	(13,842)
Cash flows from investing activities
Purchase of short-term investments	(24,953)
Maturities of short-term investments	3,992
Purchase of property and equipment	(1,978)	(804)
Net cash used in investing activities	(22,939)	(804)
Cash flows from financing activities
Proceeds from debt issuance, net of issuance costs	14,717
Principal payments on notes payable	(1,272)	(975)
Proceeds from issuance of common stock, net of issuance costs	32,649	14,159
Proceeds from exercise of stock options	53	1
Net cash provided by financing activities	46,147	13,185
Net decrease in cash and cash equivalents	(1,602)	(1,461)
Cash and cash equivalents — beginning of period	11,477	19,113
Cash and cash equivalents — end of period	9,875	17,652
Supplemental disclosure:
Cash paid for interest	28	112
Cash paid for taxes	1
Issuance of warrant for 277,778 shares of Class A Common Stock issued in connection with debt	$ 227

Condensed Consolidated Stateme8

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals)	Sep. 30, 2017shares
Issuance of Warrant, Redeemable Shares (in shares)	227,778

Note 1 - Description of Busines

Note 1 - Description of Business	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Nature of Operations [Text Block]	NOTE 1 – DESCRIPTION OF BUSINESS AirXpanders, Inc. and its Australian branch (“AirXpanders” or the “Company”) is a Delaware corporation formed on March 17, 2005, two 2016, first 2012

Note 2 - Liquidity

Note 2 - Liquidity	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2 – LIQUIDITY The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has incurred net losses and cash flow deficits from operations since its inception and has an accumulated deficit of $ 87.6 September 30, 2017. 2015, 2017. The Company believes our current cash balances will be sufficient to meet our anticipated cash requirements to fund our commercial launch of AeroForm in the United States in 2017, twelve The accompanying consolidated financial statements do not may

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying condensed consolidated financial statements and related financial information are unaudited and should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2016 10, July 17, 2017. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP) and the applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2016 not ’s financial information. The results of operations for the three nine September 30, 2017 not December 31, 2017 no Foreign Currency The Company transacts business in Australia. The functional currency of its branch office in Australia is the U.S. dollar. Monetary assets and liabilities are translated at the year-end exchange rate and non-monetary assets and liabilities are translated at historical rates and items in the statement of operations are translated at average rates with gains and losses from remeasurement being recorded in other expense (income), net in the accompanying condensed consolidated statements of operations and comprehensive loss. Foreign currency translation and remeasurement gains or losses included in other expense (income), net in the accompanying condensed consolidated statements of operations and comprehensive loss was a loss of $9,000 $28,000 three September 30, 2017 2016, $35,000 $37,000 nine September 30, 2017 2016, Use of Estimates The preparation of the accompanying condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. The Company’s most significant estimates relate to sales returns and allowances, the valuation of its common stock prior to the IPO, valuation of stock options and valuation of its inventory at the lower of cost or market. Concentrations of Credit Risk Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company maintains all of its U.S. cash balances at one may $250,000 September 30, 2017 December 31, 2016, $9.4 $10.8 one may $195,000 250,000 September 30, 2017 no December 31, 2016, $0.8 Cash, Cash Equivalents and Short-Term Investments The Company considers all highly liquid investments with an original maturity of three September 30, 2017, may September 30, 2017 December 31, 2016, $30.6 $10.5 one $0.2 $1.0 one Inventory Inventory is valued at the lower of cost or market value, with cost determined by the first first Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, generally three five three five Expenditures for repairs and maintenance are charged to expense as incurred. Upon disposition of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statement of operations. Impairment of Long-Lived Assets The Company's long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not As of September 30, 2017 December 31, 2016, not Fair Value of Financial Instruments The Company follows Financial Accounting Standards Board ("FASB") Accounting Standards Codification Topic No. 820, 820" 820 As defined in ASC 820, 820 three Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 not Level 3 – Unobservable inputs that are supported by little or no The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following table sets forth by level, within the fair value hierarchy, the Company ’s assets measured at fair value on a recurring basis in the balance sheet as of the following dates (in thousands): September 30, 2017 Fair Value Measurements Using Input Types Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 9,875 $ — $ — $ 9,875 Short-term investments 20,946 — — 20,946 Total assets at fair value $ 30,821 $ - $ — $ 30,821 December 31, 2016 Fair Value Measurements Using Input Types Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 11,477 $ — $ — $ 11,477 Total assets at fair value $ 11,477 $ — $ — $ 11,477 Long-term debt is valued at carrying value which is considered to be representative of its fair value based on current market rates available to the Company for comparable borrowing facilities as well as due to its short time of maturity (Level 2 Revenue Recognition The Company recognizes revenue from sales of its products in accordance with the Revenue Recognition Topic ASC 605. four thirty . les returns based on historical experience, recent gross sales and any notification of pending returns. The Company recognizes revenue when title to the product and risk of loss transfer to customers, provided there are no thirty may Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are stated at cost, net of allowance for doubtful accounts. Credit is extended to customers based on an evaluation of their financial condition and other factors. The Company does not not The Company estimates its allowance for doubtful accounts by evaluating specific accounts where information indicates that customers may may ’s customer analysis, it did not September 30, 2017 December 31, 2016. Concentration Five customers contributed 23% 54%, three September 30, 2017 2016. 25% 63%, nine September 30, 2017 2016. 36% September 30, 2017. 58% September 30, 2016. 85% 74% three nine months ended September 30, 2017, three nine September 30, 2016 Stock-Based Compensation Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The expense recognized for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate. The forfeiture rate is determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company uses the Black-Scholes option-pricing model (the "Black-Scholes model") as the method for determining the estimated fair value of stock options. Expected Term The Company's expected term represents the period that the Company's stock-based awards are expected to be outstanding and is determined using the simplified method, which essentially equates to a weighted average of the vesting periods and total term of the award. Expected Volatility Expected volatility is estimated using comparable public company ’s volatility for similar terms as the Company does not Expected Dividend The Black-Scholes model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no Risk-Free Interest Rate The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury zero The Company recognizes the fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received. Research and Development Costs incurred in research and development activities (including clinical trials) are expensed as incurred. Research and development costs include, but are not Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are recorded based on the estimated future tax effects of differences between the financial statement and income tax basis of assets and liabilities. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating loss and tax credit carryovers. Deferred tax assets and liabilities are measured using the enacted tax rates applied to taxable income. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided against the Company ’s deferred income tax assets when it is more likely than not not Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, the Company considers all available evidence, including past operating results, estimates of future taxable income and the feasibility of tax planning strategies. In the event that the Company changes its determination as to the amount of deferred tax assets that are more likely than not The Company follows authoritative guidance regarding uncertain tax positions. This guidance requires that realization of an uncertain income tax position must be more likely than not 50% Segments The Company has determined the chief executive officer is the chief operating decision maker. The Company ’s chief executive officer reviews financial information presented for purposes of assessing performance and making decisions on how to allocate resources. The Company has determined that it operates in a single reporting segment. Basic and Diluted Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential shares of common stock, resulting from the conversion or exercise of stock options, stock warrants, convertible debt and convertible preferred stock to the extent dilutive. For the periods presented, all such common stock equivalents have been excluded from diluted net loss per share as the effect to net loss per share would be anti-dilutive. Following is a table summarizing the potentially dilutive common shares that were excluded from diluted weighted-average common shares outstanding for the three nine September 30, 2017 2016, 2017 2016 Shares of common stock issuable upon exercise of warrants 615 337 Shares of common stock issuable upon exercise of stock options 6,404 5,226 Potential common shares excluded from diluted net loss per share 7,019 5,563 Recent Accounting Pronouncements In May 2017, 2017 09, —Stock Compensation (Topic 718 first 2018. not The Company assesses the adoption impact of recently issued accounting standards by the Financial Accounting Standards Board on our financial statements. The above describes the impact of newly issued standards as well as material updates to our previous assessments, if any, from our audited financial statements included in our registration statement on Form 10, July 17, 2017.

Note 4 - Inventory

Note 4 - Inventory	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 4 – INVENTORY Inventory consisted of the following at (in thousands): September 30, December 31, 2017 2016 Raw materials $ 2,150 $ 760 Work in progress 3,206 439 Finished goods 1,073 214 Inventory $ 6,429 $ 1,413 The Company had recorded inventory provisions and write-downs to inven tory to market value by $0.4 $0.6 three September 30, 2017 2016, $3.1 $1.0 nine September 30, 2017 2016,

Note 5 - Property and Equipment

Note 5 - Property and Equipment	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 5 – PROPERTY AND EQUIPMENT Property and equipment, net, consisted of the following at (in thousands): September 30, December 31, 2017 2016 Machinery and equipment $ 2,668 $ 1,084 Computer equipment 232 161 Furniture and fixtures 281 84 Leasehold improvements 354 170 Software licenses 277 189 Office equipment 23 11 Construction in progress 1,619 872 Property and equipment, gross 5,454 2,571 Accumulated depreciation and amortization (1,035 ) (692 ) Property and equipment, net $ 4,419 $ 1,879 Depreciation and a mortization expense amounted to $0.3 $0.3 nine September 30, 2017 2016,

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 6 – ACCRUED EXPENSES Accrued expenses consisted of the following at (in thousands): September 30, December 31, 2017 2016 Accrued compensation and benefits $ 762 $ 425 Accrued rent payable 195 69 Accrued clinical trials services - 177 Accrued inventory supplies 212 93 Accrued other 882 152 Total accrued expenses $ 2,051 $ 916

Note 7 - Debt Financing

Note 7 - Debt Financing	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 7 – DEBT FINANCING January 2014 In January 2014, $3,500,000 July 2017. 7.34% ’s assets, excluding intellectual property. Under the terms of the agreement, interest-only payments were made monthly through March 2015, April 2015, 28 $271,250 five In March 2015, March 2015 April 2015, May 2015, 27 $3,500,000 June 2015. In connection with the loan agreement and security agreement, the Company granted a warrant to the financial institution for the purchase of 52,500 $1.00 ’s IPO in June 2015 52,500 $1.00 $32,000 The Company recorded $4,000 $24,000 three September 30, 2017 2016, 31,000 $34,000 nine September 30, 2017 2016, December 31, 2016, $31,000. The Company recorded $ 30,000 $50,000 three September 30, 2017 2016, $0.1 $0.1 nine September 30, 2017 2016, December 31, 2016, $1.2 July 2017. No August 2017 In August 2017, $15,000,000 August 2022. thirty 0.99%, 7.26% assets, excluding intellectual property, which intellectual property is subject to a negative pledge in favor of the financial institution. Under the terms of the agreement, interest-only payments are due monthly through September 2019, October 2019, 35 twelve September 2020, October 2020, 23 $1,200,000 0.5% 2.0% five Under the loan and security agreement the Company is required to maintain a certain minimum level of revenues on a trailing six 2018, covenants. The loan and security agreement also includes events of default, the occurrence and continuation of any of which provides the financial institution with the right to exercise remedies against us and the collateral securing the loans, including cash. These events of default include, among other things, the failure to pay amounts due under the credit facilities, insolvency, the occurrence of a material adverse event, which includes a material adverse change in our business, operations or properties (financial or otherwise) or a material impairment of the prospect of repayment of any portion of the obligations. A violation of any of these covenants or the occurrence of a material adverse change could result in a default under the loan and security, which would result in termination of all commitments and loans under the agreement and all amounts owing under the agreement to become immediately due and payable. As of September 30, 2017, November 9, 2017, first September 30, 2017 In connection with the loan and security agreement, the Company issued warrants to the financial institution for the purchase of 277,778 $1.62 The fair value of the warrants of $227,000 The Company recorded $9,000 three nine September 30, 2017 . As of September 30, 2017, $0.5 The Company recorded $ 0.2 three nine September 30, 2017 . At September 30, 2017, $15.0

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 8 – COMMITMENTS AND CONTINGENCIES As of September 30, 2017, Year ending December 31, 2017 (remaining 3 months) $ 179 2018 835 2019 681 2020 18 2021 and beyond - Total $ 1,713 The Company maintains an inventory purchase agreements with its third The Company’s liability under this purchase commitment is generally restricted to a forecasted three September 30, 2017 $1.2 $0.2 Indemnifications The Company has agreed to indemnify its officers and directors for certain events or occurrences arising as a result of the officers or directors serving in such capacity. The Company has a directors and officers ’ liability insurance policy that limits its exposure and enables the Company to recover a portion of any future amounts paid resulting from the indemnification of its officers and directors. In addition, the Company enters into indemnification agreements with other parties in the ordinary course of business. The Company has not not September 30, 2017 December 31, 2016. Royalties The Company uses AeroForm technology in the products it is developing. AeroForm embodies inventions that have been patented in certain key jurisdictions. Certain of those patents are held by Shalon Ventures (either alone or jointly with AirXpanders). Shalon Ventures and AirXpanders have entered into a License Agreement dated March 9, 2005 ( March 9, 2009 January 9, 2012) one In consideration for the license, AirXpanders pays Shalon Ventures a running royalty of 3% $10,000, ’ out of pocket costs for prosecuting and maintaining the relevant patents. Each party indemnifies the other for any liability arising out of its material breach of the license, or its gross negligence, intentional misconduct and illegal actions. AirXpanders also indemnifies Shalon Ventures for any liability arising out of the commercialization of products using the license. For the three September 30, 2017 2016, $35,000 $5,000 nine September 30, 2017 2016, $0.1 $12,000 58%, 8%, Mr. Shalon was a director of the Company through May 2017,

Note 9 - Common Stock

Note 9 - Common Stock	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9 – COMMON STOCK The Company's Certificate of Incorporation, as amended, authorize the Company to issue 300,000,000 $0.001 200,000,000 100,000,000 not one not September 30, 2017 December 31, 2016, no September 30, 2017, 95,906,958 no In February 2017, 16,304,348 $32,648,406, $1,461,659.

Note 10 - Convertible Preferred

Note 10 - Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Preferred Stock [Text Block]	NOTE 10 – CONVERTIBLE PREFERRED STOCK The Company's Certificate of Incorporation, as amended, authorizes the Company to issue 10,000,000 ’s Board of Directors before issuing preferred shares. At September 30, 2017 December 31, 2016, no

Note 11 - Stock-based Compensat

Note 11 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	NOTE 1 1 – STOCK-BASED COMPENSATION The fair value of stock options is estimated on the grant date using the Black-Scholes valuation model and the assumptions noted in the following table. Nine Months Ended September 30, 2017 2016 Expected terms (years) 5.27 - 10.0 5.54 - 6.08 Volatility 31.9 - 40.7% 33.8 - 34.9% Risk-free rate 1.8 - 2.4% 1.18 - 1.43% Dividend yield —% —% Activity under the Plan is set forth below: Weighted Weighted Average Average Options Number of Exercise Remaining Available Options Price Contractual for Grant Outstanding per Share Life in Years Balance — December 31, 2016 1,600,878 5,355,702 $ 0.92 6.6 Additional shares reserved 1,584,834 — Options granted (1,709,517 ) 1,709,517 $ 1.90 Options exercised — (385,386 ) $ 0.29 Shares traded for option exercises 27,771 — Options forfeited/cancelled/repurchase 122,867 (122,867 ) $ 1.54 Balance — September 30, 2017 1,626,833 6,556,966 $ 1.20 7.0 Vested or expected to vest at September 6,403,907 $ 1.18 7.0 Exercisable at September 4,103,232 $ 0.65 5.7 In connection with the grant of stock options to employees and non-employees, the Company recorded stock compensation expense as follows (in thousands): Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Cost of goods sold $ 29 $ 6 $ 73 $ 30 Research and development 13 7 38 28 Selling, general and administrative 133 125 422 258 Total $ 175 $ 138 $ 533 $ 316

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying condensed consolidated financial statements and related financial information are unaudited and should be read in conjunction with the audited financial statements and the related notes thereto for the year ended December 31, 2016 10, July 17, 2017. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (US GAAP) and the applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted, and accordingly the balance sheet as of December 31, 2016 not ’s financial information. The results of operations for the three nine September 30, 2017 not December 31, 2017 no
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The Company transacts business in Australia. The functional currency of its branch office in Australia is the U.S. dollar. Monetary assets and liabilities are translated at the year-end exchange rate and non-monetary assets and liabilities are translated at historical rates and items in the statement of operations are translated at average rates with gains and losses from remeasurement being recorded in other expense (income), net in the accompanying condensed consolidated statements of operations and comprehensive loss. Foreign currency translation and remeasurement gains or losses included in other expense (income), net in the accompanying condensed consolidated statements of operations and comprehensive loss was a loss of $9,000 $28,000 three September 30, 2017 2016, $35,000 $37,000 nine September 30, 2017 2016,
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the accompanying condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. The Company’s most significant estimates relate to sales returns and allowances, the valuation of its common stock prior to the IPO, valuation of stock options and valuation of its inventory at the lower of cost or market.
Cash, Cash Equivalents, and Short-term Investments, Policy [Policy Text Block]	Concentrations of Credit Risk Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents. The Company maintains all of its U.S. cash balances at one may $250,000 September 30, 2017 December 31, 2016, $9.4 $10.8 one may $195,000 250,000 September 30, 2017 no December 31, 2016, $0.8 Cash, Cash Equivalents and Short-Term Investments The Company considers all highly liquid investments with an original maturity of three September 30, 2017, may September 30, 2017 December 31, 2016, $30.6 $10.5 one $0.2 $1.0 one
Inventory, Policy [Policy Text Block]	Inventory Inventory is valued at the lower of cost or market value, with cost determined by the first first
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets, generally three five three five Expenditures for repairs and maintenance are charged to expense as incurred. Upon disposition of an asset, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in the statement of operations.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company's long-lived assets and other assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not As of September 30, 2017 December 31, 2016, not
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company follows Financial Accounting Standards Board ("FASB") Accounting Standards Codification Topic No. 820, 820" 820 As defined in ASC 820, 820 three Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 not Level 3 – Unobservable inputs that are supported by little or no The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following table sets forth by level, within the fair value hierarchy, the Company ’s assets measured at fair value on a recurring basis in the balance sheet as of the following dates (in thousands): September 30, 2017 Fair Value Measurements Using Input Types Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 9,875 $ — $ — $ 9,875 Short-term investments 20,946 — — 20,946 Total assets at fair value $ 30,821 $ - $ — $ 30,821 December 31, 2016 Fair Value Measurements Using Input Types Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 11,477 $ — $ — $ 11,477 Total assets at fair value $ 11,477 $ — $ — $ 11,477 Long-term debt is valued at carrying value which is considered to be representative of its fair value based on current market rates available to the Company for comparable borrowing facilities as well as due to its short time of maturity (Level 2
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue from sales of its products in accordance with the Revenue Recognition Topic ASC 605. four thirty . les returns based on historical experience, recent gross sales and any notification of pending returns. The Company recognizes revenue when title to the product and risk of loss transfer to customers, provided there are no thirty may
Trade and Other Accounts Receivable, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are stated at cost, net of allowance for doubtful accounts. Credit is extended to customers based on an evaluation of their financial condition and other factors. The Company does not not The Company estimates its allowance for doubtful accounts by evaluating specific accounts where information indicates that customers may may ’s customer analysis, it did not September 30, 2017 December 31, 2016.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration Five customers contributed 23% 54%, three September 30, 2017 2016. 25% 63%, nine September 30, 2017 2016. 36% September 30, 2017. 58% September 30, 2016. 85% 74% three nine months ended September 30, 2017, three nine September 30, 2016
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The expense recognized for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate. The forfeiture rate is determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company uses the Black-Scholes option-pricing model (the "Black-Scholes model") as the method for determining the estimated fair value of stock options. Expected Term The Company's expected term represents the period that the Company's stock-based awards are expected to be outstanding and is determined using the simplified method, which essentially equates to a weighted average of the vesting periods and total term of the award. Expected Volatility Expected volatility is estimated using comparable public company ’s volatility for similar terms as the Company does not Expected Dividend The Black-Scholes model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no Risk-Free Interest Rate The risk-free interest rate used in the Black-Scholes model is based on the U.S. Treasury zero The Company recognizes the fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs incurred in research and development activities (including clinical trials) are expensed as incurred. Research and development costs include, but are not
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are recorded based on the estimated future tax effects of differences between the financial statement and income tax basis of assets and liabilities. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating loss and tax credit carryovers. Deferred tax assets and liabilities are measured using the enacted tax rates applied to taxable income. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided against the Company ’s deferred income tax assets when it is more likely than not not Significant judgment is required in determining any valuation allowance recorded against deferred tax assets. In assessing the need for a valuation allowance, the Company considers all available evidence, including past operating results, estimates of future taxable income and the feasibility of tax planning strategies. In the event that the Company changes its determination as to the amount of deferred tax assets that are more likely than not The Company follows authoritative guidance regarding uncertain tax positions. This guidance requires that realization of an uncertain income tax position must be more likely than not 50%
Segment Reporting, Policy [Policy Text Block]	Segments The Company has determined the chief executive officer is the chief operating decision maker. The Company ’s chief executive officer reviews financial information presented for purposes of assessing performance and making decisions on how to allocate resources. The Company has determined that it operates in a single reporting segment.
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential shares of common stock, resulting from the conversion or exercise of stock options, stock warrants, convertible debt and convertible preferred stock to the extent dilutive. For the periods presented, all such common stock equivalents have been excluded from diluted net loss per share as the effect to net loss per share would be anti-dilutive. Following is a table summarizing the potentially dilutive common shares that were excluded from diluted weighted-average common shares outstanding for the three nine September 30, 2017 2016, 2017 2016 Shares of common stock issuable upon exercise of warrants 615 337 Shares of common stock issuable upon exercise of stock options 6,404 5,226 Potential common shares excluded from diluted net loss per share 7,019 5,563
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2017, 2017 09, —Stock Compensation (Topic 718 first 2018. not The Company assesses the adoption impact of recently issued accounting standards by the Financial Accounting Standards Board on our financial statements. The above describes the impact of newly issued standards as well as material updates to our previous assessments, if any, from our audited financial statements included in our registration statement on Form 10, July 17, 2017.

Note 3 - Summary of Significa21

Note 3 - Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	September 30, 2017 Fair Value Measurements Using Input Types Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 9,875 $ — $ — $ 9,875 Short-term investments 20,946 — — 20,946 Total assets at fair value $ 30,821 $ - $ — $ 30,821 December 31, 2016 Fair Value Measurements Using Input Types Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 11,477 $ — $ — $ 11,477 Total assets at fair value $ 11,477 $ — $ — $ 11,477
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2017 2016 Shares of common stock issuable upon exercise of warrants 615 337 Shares of common stock issuable upon exercise of stock options 6,404 5,226 Potential common shares excluded from diluted net loss per share 7,019 5,563

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, December 31, 2017 2016 Raw materials $ 2,150 $ 760 Work in progress 3,206 439 Finished goods 1,073 214 Inventory $ 6,429 $ 1,413

Note 5 - Property and Equipme23

Note 5 - Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, December 31, 2017 2016 Machinery and equipment $ 2,668 $ 1,084 Computer equipment 232 161 Furniture and fixtures 281 84 Leasehold improvements 354 170 Software licenses 277 189 Office equipment 23 11 Construction in progress 1,619 872 Property and equipment, gross 5,454 2,571 Accumulated depreciation and amortization (1,035 ) (692 ) Property and equipment, net $ 4,419 $ 1,879

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	September 30, December 31, 2017 2016 Accrued compensation and benefits $ 762 $ 425 Accrued rent payable 195 69 Accrued clinical trials services - 177 Accrued inventory supplies 212 93 Accrued other 882 152 Total accrued expenses $ 2,051 $ 916

Note 8 - Commitments and Cont25

Note 8 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year ending December 31, 2017 (remaining 3 months) $ 179 2018 835 2019 681 2020 18 2021 and beyond - Total $ 1,713

Note 11 - Stock-based Compens26

Note 11 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine Months Ended September 30, 2017 2016 Expected terms (years) 5.27 - 10.0 5.54 - 6.08 Volatility 31.9 - 40.7% 33.8 - 34.9% Risk-free rate 1.8 - 2.4% 1.18 - 1.43% Dividend yield —% —%
Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Weighted Average Average Options Number of Exercise Remaining Available Options Price Contractual for Grant Outstanding per Share Life in Years Balance — December 31, 2016 1,600,878 5,355,702 $ 0.92 6.6 Additional shares reserved 1,584,834 — Options granted (1,709,517 ) 1,709,517 $ 1.90 Options exercised — (385,386 ) $ 0.29 Shares traded for option exercises 27,771 — Options forfeited/cancelled/repurchase 122,867 (122,867 ) $ 1.54 Balance — September 30, 2017 1,626,833 6,556,966 $ 1.20 7.0 Vested or expected to vest at September 6,403,907 $ 1.18 7.0 Exercisable at September 4,103,232 $ 0.65 5.7
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 Cost of goods sold $ 29 $ 6 $ 73 $ 30 Research and development 13 7 38 28 Selling, general and administrative 133 125 422 258 Total $ 175 $ 138 $ 533 $ 316

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Retained Earnings (Accumulated Deficit)	$ (87,647)	$ (66,328)

Note 3 - Summary of Significa28

Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Impairment of Long-Lived Assets Held-for-use			$ 0		$ 0
Allowance for Doubtful Accounts Receivable, Current	$ 0		$ 0		0
Number of Reportable Segments			1
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Five Customers [Member]
Concentration Risk, Percentage	23.00%	54.00%	25.00%	63.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Five Customers [Member]
Concentration Risk, Percentage			36.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Customers [Member]
Concentration Risk, Percentage				58.00%
Minimum [Member]
Property, Plant and Equipment, Useful Life			3 years
Minimum [Member] | Construction in Progress [Member]
Property, Plant and Equipment, Useful Life			3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life			5 years
Maximum [Member] | Construction in Progress [Member]
Property, Plant and Equipment, Useful Life			5 years
UNITED STATES
Cash, Uninsured Amount	$ 9,400,000		$ 9,400,000		10,800,000
Cash, Cash Equivalents, and Short-term Investments	$ 30,600,000		$ 30,600,000		10,500,000
UNITED STATES | Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Hospitals [Member]
Concentration Risk, Percentage	85.00%		74.00%
AUSTRALIA
Cash, Uninsured Amount	$ 0		$ 0		800,000
Cash, Cash Equivalents, and Short-term Investments	200,000		200,000		$ 1,000,000
Other Nonoperating Income (Expense) [Member]
Foreign Currency Transaction Gain (Loss), before Tax	$ (9,000)	$ 28,000	$ 35,000	$ 37,000

Note 3 - Summary of Significa29

Note 3 - Summary of Significant Accounting Policies - Fair Value of Assets Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Cash and cash equivalents	$ 9,875	$ 11,477
Short-term investments	20,946
Total assets at fair value	30,821	11,477
Fair Value, Inputs, Level 1 [Member]
Cash and cash equivalents	9,875	11,477
Short-term investments	20,946
Total assets at fair value	30,821	11,477
Fair Value, Inputs, Level 2 [Member]
Cash and cash equivalents
Short-term investments
Total assets at fair value
Fair Value, Inputs, Level 3 [Member]
Cash and cash equivalents
Short-term investments
Total assets at fair value

Note 3 - Summary of Significa30

Note 3 - Summary of Significant Accounting Policies - Summary of Potentially Dilutive Shares Excluded From Weighted Average Diluted Shares Outstanding (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Antidilutive securities (in shares)	7,019	5,563
Warrant [Member]
Antidilutive securities (in shares)	615	337
Employee Stock Option [Member]
Antidilutive securities (in shares)	6,404	5,226

Note 4 - Inventory (Details Tex

Note 4 - Inventory (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Inventory Write-down	$ 400	$ 600	$ 3,143	$ 578

Note 4 - Inventory - Summary of

Note 4 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Raw materials	$ 2,150	$ 760
Work in progress	3,206	439
Finished goods	1,073	214
Inventory	$ 6,429	$ 1,413

Note 5 - Property and Equipme33

Note 5 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Depreciation, Depletion and Amortization	$ 343	$ 226

Note 5 - Property and Equipme34

Note 5 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Property and equipment, gross	$ 5,454	$ 2,571
Accumulated depreciation and amortization	(1,035)	(692)
Property and equipment, net	4,419	1,879
Machinery and Equipment [Member]
Property and equipment, gross	2,668	1,084
Computer Equipment [Member]
Property and equipment, gross	232	161
Furniture and Fixtures [Member]
Property and equipment, gross	281	84
Leasehold Improvements [Member]
Property and equipment, gross	354	170
Software and Software Development Costs [Member]
Property and equipment, gross	277	189
Office Equipment [Member]
Property and equipment, gross	23	11
Construction in Progress [Member]
Property and equipment, gross	$ 1,619	$ 872

Note 6 - Accrued Expenses - Sum

Note 6 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Accrued compensation and benefits	$ 762	$ 425
Accrued rent payable	195	69
Accrued clinical trials services		177
Accrued inventory supplies	212	93
Accrued other	882	152
Total accrued expenses	$ 2,051	$ 916

Note 7 - Debt Financing (Detail

Note 7 - Debt Financing (Details Textual)	1 Months Ended				3 Months Ended		9 Months Ended
	Aug. 31, 2017USD ($)$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	Mar. 31, 2015USD ($)	Jan. 31, 2014USD ($)$ / sharesshares	Sep. 30, 2017USD ($)shares	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)shares	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares					227,778		227,778
Amortization of Debt Issuance Costs and Discounts							$ 107,000	$ 30,000
Long-term Debt, Current Maturities									$ 1,195,000
Series E Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				52,500
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 1
Class of Warrant or Right, Issued During Period | shares		52,500
Class of Warrant or Right, Issued During Period, Exercise Price | $ / shares		$ 1
Debt Instrument, Unamortized Discount		$ 32,000
Warrants Issued in Connection with Loan and Security Agreement 2 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	277,778
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.62
Warrants and Rights Outstanding	$ 227,000
Loan and Security Agreement [Member]
Proceeds from Issuance of Debt				$ 3,500,000
Debt Instrument, Interest Rate, Stated Percentage				7.34%
Debt Instrument, Number of Equal Monthly Installments			27	28
Debt Instrument, Fee Amount				$ 271,250
Debt Instrument, Additional Option to Borrow			$ 3,500,000
Amortization of Debt Issuance Costs and Discounts					4,000	$ 24,000	31,000	34,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net									31,000
Interest Expense, Debt					30,000	$ 50,000	100,000	$ 100,000
Long-term Debt, Current Maturities									$ 1,200,000
Loan and Security Agreement 2 [Member]
Proceeds from Issuance of Debt	$ 15,000,000
Debt Instrument, Number of Equal Monthly Installments	35
Debt Instrument, Fee Amount	$ 1,200,000
Amortization of Debt Issuance Costs and Discounts					9,000		9,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net					500,000		500,000
Interest Expense, Debt					200,000		200,000
Debt Instrument, Variable Rate	0.99%
Debt Instrument, Basis Spread on Variable Rate	7.26%
Debt Instrument, Number of Equal Monthly Installments When Compliant with Certain Financial Milestones	23
Long-term Debt					$ 15,000,000		$ 15,000,000
Loan and Security Agreement 2 [Member] | Minimum [Member]
Debt Instrument, Prepayment Fee, Percentage	0.50%
Loan and Security Agreement 2 [Member] | Maximum [Member]
Debt Instrument, Prepayment Fee, Percentage	2.00%

Note 8 - Commitments and Cont37

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Purchase Commitment, Remaining Minimum Amount Committed	$ 1,200,000		$ 1,200,000
Inventory Write-down	400,000	$ 600,000	$ 3,143,000	$ 578,000
Shalon Ventures License Agreement [Member]
Royalty Expense, Percentage of Net Sales			3.00%
Royalty Expense, Threshold Amount for Additional Costs			$ 10,000
Shalon Ventures License Agreement [Member] | Chief Executive Officer [Member] | Shalon Ventures [Member]
Royalty Revenue, Percentage			58.00%
Shalon Ventures License Agreement [Member] | Board of Directors Chairman [Member]
Royalty Revenue, Percentage			8.00%
Shalon Ventures License Agreement [Member] | Cost of Sales [Member]
Royalty Expense	$ 35,000	$ 5,000	$ 100,000	$ 12,000
Purchase Commitment [Member] | Accrued Expenses [Member]
Inventory Write-down			$ 200,000

Note 8 - Commitments and Cont38

Note 8 - Commitments and Contingencies - Future Rental Commitments (Details) $ in Thousands	Sep. 30, 2017USD ($)
2017 (remaining 3 months)	$ 179
2,018	835
2,019	681
2,020	18
2021 and beyond
Total	$ 1,713

Note 9 - Common Stock (Details

Note 9 - Common Stock (Details Textual) - USD ($)	1 Months Ended	9 Months Ended	12 Months Ended
	Feb. 28, 2017	Sep. 30, 2017	Dec. 31, 2016
Common Stock, Shares Authorized		300,000,000
Common Stock, Par or Stated Value Per Share		$ 0.001
Dividends, Common Stock		$ 0	$ 0
Stock Issued During Period, Shares, New Issues	16,304,348
Stock Issued During Period, Value, New Issues	$ 32,648,406	$ 32,649,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	$ 1,461,659
Common Class A [Member]
Common Stock, Shares Authorized		200,000,000	200,000,000
Common Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Common Stock, Shares, Issued		95,906,958	79,241,708
Common Stock, Shares, Outstanding		95,906,958	79,241,708
Common Class B [Member]
Common Stock, Shares Authorized		100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Common Stock, Shares, Issued		0	0
Common Stock, Shares, Outstanding		0	0

Note 10 - Convertible Preferr40

Note 10 - Convertible Preferred Stock (Details Textual) - shares	Sep. 30, 2017	Dec. 31, 2016
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Outstanding	0	0

Note 11 - Stock-based Compens41

Note 11 - Stock-based Compensation - Fair Value Assumptions for Stock Options (Details) - Employee Stock Option [Member]	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Dividend yield
Minimum [Member]
Expected terms (Year)	5 years 98 days	5 years 197 days
Volatility	31.90%	33.80%
Risk-free rate	1.80%	1.18%
Maximum [Member]
Expected terms (Year)	10 years	6 years 29 days
Volatility	40.70%	34.90%
Risk-free rate	2.40%	1.43%

Note 11 - Stock-based Compens42

Note 11 - Stock-based Compensation - Stock Option Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Options available for grant (in shares)	1,600,878
Number of options outstanding (in shares)	5,355,702
Weighted average exercise price per share (in dollars per share)	$ 0.92
Weighted average remaining contractual life (Year)	7 years	6 years 219 days
Additional shares reserved (in shares)	1,584,834
Options available for grant, options granted (in shares)	(1,709,517)
Number of options outstanding, options granted (in shares)	1,709,517
Weighted average exercise price per share, options granted (in dollars per share)	$ 1.90
Number of options outstanding, options exercised (in shares)	(385,386)
Weighted average exercise price per share, options exercised (in dollars per share)	$ 0.29
Exercise of stock options and warrants, 388,673 shares net of 27,771 shares traded for exercise price (in shares)	27,771
Options available for grant, options forfeited/cancelled/repurchase (in shares)	122,867
Number of options outstanding, options forfeited/cancelled/repurchase (in shares)	(122,867)
Weighted average exercise price per share, options forfeited/cancelled/repurchase (in dollars per share)	$ 1.54
Options available for grant (in shares)	1,626,833	1,600,878
Number of options outstanding (in shares)	6,556,966	5,355,702
Weighted average exercise price per share (in dollars per share)	$ 1.20	$ 0.92
Number of options outstanding, vested or expected to vest (in shares)	6,403,907
Weighted average exercise price per share, vested or expected to vest (in dollars per share)	$ 1.18
Weighted average remaining contractual life, vested or expected to vest (Year)	7 years
Number of options outstanding, exercisable (in shares)	4,103,232
Weighted average exercise price per share, exercisable (in dollars per share)	$ 0.65
Weighted average remaining contractual life, exercisable (Year)	5 years 255 days

Note 11 - Stock-based Compens43

Note 11 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Stock-based compensation expense	$ 175	$ 138	$ 533	$ 316
Cost of Sales [Member]
Stock-based compensation expense	29	6	73	30
Research and Development Expense [Member]
Stock-based compensation expense	13	7	38	28
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 133	$ 125	$ 422	$ 258